Generate Biomedicines (NASDAQ:GENB) Upgraded at Wall Street Zen

Generate Biomedicines (NASDAQ:GENB) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts have also weighed in on GENB. HC Wainwright raised their target price on shares of Generate Biomedicines from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday. Morgan Stanley increased their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings initiated coverage on Generate Biomedicines in a report on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Generate Biomedicines has an average rating of “Moderate Buy” and an average target price of $26.40.

Generate Biomedicines Trading Down 2.8%

Generate Biomedicines stock traded down $0.44 during midday trading on Friday, reaching $15.33. The company’s stock had a trading volume of 2,353,064 shares, compared to its average volume of 1,181,209. The firm has a market cap of $1.97 billion and a PE ratio of -9.64. Generate Biomedicines has a 52 week low of $11.00 and a 52 week high of $22.67. The firm’s 50-day moving average is $15.27.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. Research analysts anticipate that Generate Biomedicines will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Generate Biomedicines

Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System acquired a new position in Generate Biomedicines in the 2nd quarter valued at approximately $96,000. AXQ Capital LP acquired a new position in shares of Generate Biomedicines during the second quarter worth $218,000. Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines in the second quarter worth $967,000. Braidwell LP bought a new stake in shares of Generate Biomedicines in the second quarter worth $55,398,000. Finally, Susquehanna International Group LLP acquired a new stake in Generate Biomedicines in the second quarter valued at $196,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.